Members

Prof. Elisabetta Bugianesi MD, PhD, is an internationally acknowledged expert on NAFLD. She has made a particular impact within research focused the metabolic mechanisms of insulin resistance related to the onset and progression of liver damage; the natural history of the disease, including the first demonstration of HCC as a complication of NASH-related liver disease; and the development of non-invasive markers of fibrosis. She is a national principal investigator for the FLIP (Fatty Liver: Inhibition of Progression) consortium, assembling the largest cohort to date of highly phenotyped, histologically characterized patients with NAFLD for the genetics work package. She is also involved in the EU-funded research consortium EPoS (Elucidating Pathways of Steatohepatitis) and Italy’s national lead for the LITMUS (Liver Investigation: Testing Marker Utility in Steatohepatitis) consortium.

As clinician, Prof. Bugianesi is a practicing hepatologist based at the GI Division of the University Hospital “Città della Salute e della Scienza of Torino,” Italy, where she is the lead physician for the Hepatology Outpatient Clinic and the Head of the Gastro-hepatology Laboratory.

Prof. Bugianesi obtained her MD from the School of Medicine of the University of Bologna and her PhD in Hepatology at the University of Bologna and Modena. Her post-graduate training included a PhD fellowship at the Cleveland Clinic and Case Western Reserve where she became expert in the use of stable isotopes to study in vivo metabolism and started a pioneering research activity on NAFLD under the guidance of Prof AJ McCullough.

Next »